purpose: to assess the short-term effect of mitomycin-c (mmc) 0.02% on endothelial cell density and morphology after photorefractive keratectomy (prk) in patients with moderate myopia. methods: forty-two eyes of 21 participants with moderate myopia (range, -4.0 to -8.0 d) underwent prk with mmc 0.02% for 40 seconds. specular microscopy was performed preoperatively and repeated 6 months after su...

Mitomycin C is an antimetabolite agent that blocks DNA and RNA replication and protein synthesis. It has been used in several ophthalmologic areas, and recently as a modulator of corneal wound healing in excimer laser surgeries. A single application of mitomycin C during surface corneal photoablative surgery seems a safe and efficient therapeutic option for eyes with corneal opacity and/or as p...

Mitomycin-C is a chemotherapeutic drug that acts by inhibiting DNA synthesis. Its use and application in ophthalmology has been increasing in recent years because of its mandatory effects on wound healing. Current applications include pterygium surgery, glaucoma surgery, corneal refractive surgery, cictracial eye disease, conjunctivalneoplasia, dacryocystorhinostomy surgeries and allergic eye d...

The aim of the present meta-analysis was to compare the benefits of Bacillus Calmetter-Guerin (BCG) and mitomycin C in the treatment of patients with superficial bladder cancer. The present meta-analysis analyzed the benefits of BCG and mitomycin C in the treatment of patients with superficial bladder cancer by comparing progression-free survival (PFS) rates in patients treated with either of t...

Objective (s): This study aimed at investigation of preparation and stability study of Mitomycin and Mitomycin loaded nanoliposems and efficacy of the combination of Mitomycin -loaded nanoliposomes and Curcumin versus Mitomycin in suppressing HTB-9 and L929 cell lines, in vitro.Materials and Methods: An HPLC method was validated based on Q2 (R1) International Conference on Harmonization (ICH) g...

Durham, Norman N. (Oklahoma State University, Stillwater). Inhibition of microbial growth and separation by d-serine, vancomycin, and mitomycin C. J. Bacteriol. 86:380-386. 1963.-A study was made of the growth and separation inhibition of Pseudomonas fluorescens by vancomycin and mitomycin C and of a Flavobacterium sp. sensitive to mitomycin C and d-serine. Aberrant morphological forms (primari...

OBJECTIVE To compare the rate of recurrence and complications of pterygium following surgical excision by applying 0.02% mitomycin-C intraoperatively or using topical 0.02 % mitomycin-C drops postoperatively. STUDY DESIGN Randomized clinical trial. PLACE AND DURATION OF STUDY Baqai Medical University Hospital, Department of Ophthalmology, from January 2001 to July 2005. METHODOLOGY Eighty...

AIMS To demonstrate the efficacy of mitomycin C as adjuvant therapy preoperatively and intraoperatively in the management of recurrent or diffuse ocular surface neoplasias. METHODS The case notes of 11 patients receiving mitomycin C adjuvant therapy as 0.04% eye drops four times a day in two weekly courses preoperatively and/or a single intraoperative application of 0.4 mg/ml of mitomycin C w...

AIM The study was designed to evaluate the long term results of intraoperative mitomycin C in patients with one recurrence of pterygium. METHODS In 45 white patients with one recurrence of pterygium the 'bare sclera technique' was performed and a sterile sponge soaked in a 0.2 mg/ml (0.02%) mitomycin C solution was placed intraoperatively on the sclera for 3 minutes. The control group underwe...

Aim: The aim of the study is to visualize the patency and measure the ostium size at the end of Endonasal DCR with mitomycin C (MMC) versus control and to assess the role of Mitomycin C in maintaining patency of nasolacrimal drainage system. Design: Prospective randomized controlled study Participants: Sixty patients who consented for this study was subjected to endonasal DCR and randomised int...